Biontech Se Stock Cash And Equivalents
| BNTX Stock | USD 108.23 6.09 5.96% |
BioNTech SE fundamentals help investors to digest information that contributes to BioNTech's financial success or failures. It also enables traders to predict the movement of BioNTech Stock. The fundamental analysis module provides a way to measure BioNTech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BioNTech stock.
BioNTech | Cash And Equivalents |
BioNTech SE Company Cash And Equivalents Analysis
BioNTech's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current BioNTech Cash And Equivalents | 9.33 B |
Most of BioNTech's fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BioNTech SE is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
BioNTech Cash And Equivalents Driver Correlations
Understanding the fundamental principles of building solid financial models for BioNTech is extremely important. It helps to project a fair market value of BioNTech Stock properly, considering its historical fundamentals such as Cash And Equivalents. Since BioNTech's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of BioNTech's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of BioNTech's interrelated accounts and indicators.
Click cells to compare fundamentals
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
In accordance with the recently published financial statements, BioNTech SE has 9.33 B in Cash And Equivalents. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The cash and equivalents for all United States stocks is significantly lower than that of the firm.
BioNTech Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BioNTech's direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BioNTech could also be used in its relative valuation, which is a method of valuing BioNTech by comparing valuation metrics of similar companies.BioNTech is currently under evaluation in cash and equivalents category among its peers.
BioNTech Current Valuation Drivers
We derive many important indicators used in calculating different scores of BioNTech from analyzing BioNTech's financial statements. These drivers represent accounts that assess BioNTech's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of BioNTech's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 2.8B | 6.4B | 15.7B | 34.1B | 23.2B | 24.4B | |
| Enterprise Value | 2.5B | 5.9B | 14.7B | 20.5B | 11.7B | 7.7B |
BioNTech ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, BioNTech's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to BioNTech's managers, analysts, and investors.Environmental | Governance | Social |
BioNTech Fundamentals
| Return On Equity | -0.024 | ||||
| Return On Asset | -0.0124 | ||||
| Profit Margin | (0.15) % | ||||
| Operating Margin | 0.02 % | ||||
| Current Valuation | 7.02 B | ||||
| Shares Outstanding | 239.74 M | ||||
| Shares Owned By Insiders | 62.30 % | ||||
| Shares Owned By Institutions | 20.65 % | ||||
| Number Of Shares Shorted | 2.02 M | ||||
| Price To Earning | 5.19 X | ||||
| Price To Book | 1.21 X | ||||
| Price To Sales | 8.05 X | ||||
| Revenue | 3.82 B | ||||
| Gross Profit | 16.07 B | ||||
| EBITDA | 1.09 B | ||||
| Net Income | 1.19 B | ||||
| Cash And Equivalents | 9.33 B | ||||
| Cash Per Share | 38.30 X | ||||
| Total Debt | 219.1 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 5.15 X | ||||
| Book Value Per Share | 79.73 X | ||||
| Cash Flow From Operations | 5.37 B | ||||
| Short Ratio | 3.00 X | ||||
| Earnings Per Share | (2.05) X | ||||
| Price To Earnings To Growth | 0.04 X | ||||
| Target Price | 128.82 | ||||
| Number Of Employees | 6.13 K | ||||
| Beta | 0.26 | ||||
| Market Capitalization | 24.49 B | ||||
| Total Asset | 23.01 B | ||||
| Retained Earnings | 19.76 B | ||||
| Working Capital | 17.46 B | ||||
| Current Asset | 284.67 M | ||||
| Current Liabilities | 143.37 M | ||||
| Net Asset | 23.01 B |
About BioNTech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BioNTech SE's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioNTech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioNTech SE based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for BioNTech Stock Analysis
When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.